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larger (phenylalanine), or polar (threonine or serine)An ‘Inside-the-Box’ Approach
amino acids. The resulting number of discrete mutantsto Drug Resistance is astronomical, and traditional methods are not equipped
to deal with the vast number of new targets. To deal
with this complexity, King et al., on page 1333–1338 of
this issue of Chemistry & Biology, illustrate an “outside-
Drug resistance is a growing problem in medicine that the-box” scientific strategy for analyzing resistance to
demands creative solutions. In this issue, Schiffer and HIV protease inhibitors [1]. Combining protein X-ray
colleagues describe their novel approach to pin- crystallography and a mathematical analysis using
pointing hot spots of resistance, which might lead to structural “envelopes”, the authors provide simple visual
new anti-HIV therapeutics [1]. tools that prominently pinpoint regions of focus for fu-
ture research. Crystal structures of HIV protease with
The introduction of HIV protease inhibitors (PIs) nearly six of the nine substrates (the remaining three are under
ten years ago revolutionized the treatment of HIV dis- continuing investigation) were generated. A mathemati-
ease. As the basis for combination regimens constitut- cal union operation upon the three-dimensional coordi-
ing highly active antiretroviral therapy (HAART), PIs nates of the six substrates was carried out to generate
turned HIV infection from a death sentence to a manage- an “envelope.” This provides a representation of the
able chronic disease that, under optimal circumstances, active site volume that must always be made available
can be held in check indefinitely. Thousands of individu- by the enzyme. Analogously, an envelope of known
als suffering from the ravages of AIDS were able to drugs is also created. Notably, the two envelopes are
recover immune competence and return to normal lives. similar but not identical. Therein lies the importance of
Despite the above unequivocal success, a dilemma this new work. The three-dimensional regions in which
remains. Because HIV is a retrovirus with a high rate of individual inhibitors protrude beyond the substrate en-
replication, it exists as a quasispecies or swarm of viral velopes are almost perfect indicators of the locations
variants in pseudoequilibrium, where potential drug- of drug-resistance mutations reported for those drugs.
resistant mutants are likely to preexist prior to therapy. The implication for future drug design of new-generation
As the role of HIV protease in the viral replication cycle HIV protease inhibitors is clear: stay “inside-the-box”!
became recognized, early researchers speculated that The principle of this inside-the-box analysis can be
resistance to PIs might be impossible since cleavage extended to other targets. The serine protease of the
of at least nine different nonhomologous substrates by hepatitus C virus (HCV) also has a finite set of substrate
the protease is required for the formation of mature, cleavage sites, and the substrate envelope for this en-
infectious viral particles. Supposedly, the enzyme would zyme could facilitate current design efforts. In a less
be unable to accommodate mutations decreasing the straightforward extension, it is possible to envision an
affinity of the active-site inhibitors without seriously envelope that would reflect an extremely high number
compromising its ability to cleave at least one of its many of discrete oligomer substrates enveloped by the HCV
substrates. Contrary to those expectations, virtually all polymerase as an approximation to its transcription of
patients in initial studies with PIs used as monotherapy a 9.6 kilobase strand of RNA. An example of application
experienced drug failure with the stepwise accumulation to drug targets in higher organisms may be found in the
of multiple mutations in the HIV protease gene [2, 3]. peptide binding site of protein kinases. In contrast to
Indeed, HIV drug resistance has become sufficiently the conserved ATP-site, the peptide substrate binding
widespread, even in the era of HAART, that it supports site is more variable between kinases and more ac-
an entire industry in HIV resistance diagnostics. Most cepting of a large variety of peptide substrate se-
resistance occurs within an individual patient as a result quences. In general, any protein with multiple substrates
of an incompletely suppressive regimen and/or poor might be subjected to this envelope analysis. In the case
adherence to the regimen (setting up a Darwinian sys- of infectious organisms, the envelope has importance
tem). However, drug-resistant HIV can also be transmit- for the consideration of drug resistance. For human drug
ted. Because HIV infection cannot be cured, there is a targets, the importance might be more for understand-
consequent need for more drugs that either prevent/ ing specificity or mechanism of action, rather than resis-
delay resistance or remain effective in patients in whom tance. With the modern improvements in protein X-ray
the virus has become resistant to current regimens. crystallographic techniques, such daunting experimen-
The traditional approach to combating drug resis- tal and analytical tasks become imaginable.
tance includes the characterization and targeting of dis- Returning to drug-resistant HIV infection, the harsh
crete mutants, enabling the identification of new com- reality is unfortunately more complex than simple math-
pounds with the proper complementarity to the mutant ematically calculated envelopes. HIV can accumulate
protein [4, 5]. However, more than 20% of the 99 amino mutations rapidly, and viral strains containing as many
acids constituting HIV protease have been known to as 10 or more resistance mutations are not uncommon.
mutate and contribute in combination to resistance to These multiple mutant proteins have the potential of
protease inhibitors. Furthermore, key mutable amino exhibiting atomic shifts both in the protein and inhibitor
that would cause any calculated envelope to undergoacids such as valine 82 can change to smaller (alanine),
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some deformation. Further confounding the envelope Kent D. Stewart and Dale J. Kempf
analysis are the mutations that appear in the substrates Global Pharmaceutical Research and Development
themselves. Although not yet present in the majority of Abbott Laboratories
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cleavage sites allow more “extreme” mutations within
the protease protein that would otherwise cripple viral
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address the functional activity of proteases, two papersCatching Proteases in Action
in this issue from Harris, et al. and Winssinger, et al.with Microarrays describe microarray technologies to identify proteases
and their substrates from complex mixtures with pep-
tide-nucleic acid (PNA)-encoded libraries of activity-
based probes [1] and fluorogenic peptide substrates [2],
Proteases regulate many essential functions in biol- respectively (Figure 1).
ogy, yet their precise roles are only beginning to be By and large, the characterization of protease sub-
unraveled. In this issue, two related papers describe strates has been determined with purified proteins or
a novel method to dissect specific protease activities peptide libraries in vitro, which then suggests potential
from complex mixtures [1, 2]. substrates in vivo. The development of positional-scan-
ning fluorogenic-substrate libraries has allowed the
characterization of preferred amino acids at the site ofProteolysis provides an irreversible means to activate
proteolysis and has been used to determine the substrateor terminate signaling events in complex biological set-
specificities for several protease families in a high-through-tings by destruction of proteins. With greater than 500
put manner [7–9]. Using these positional-scanning sub-putative protease genes in the typical mammalian ge-
strate libraries, Harris, et al. evaluated the proteolytic activ-nome, understanding their precise roles in biology is
ities in dust mite extracts that may be responsible fordaunting [3]. The generation of protease-deficient mice
allergies [1]. By including class-specific protease inhibi-and small-molecule inhibitors has revealed essential
tors, they showed that the predominant proteolytic ac-functions for proteases in many areas of biology, ranging
tivities in dust mite extracts that cleaved P1 basic resi-from cell cycle control [4] to antigen presentation [5]
dues were attributed to cysteine proteases, whereasand extracellular matrix remodeling [6]. Functional re-
serine proteases were responsible for cleaving sub-dundancy within protease subfamilies and limited meth-
strates with P1 proline residues. Although these posi-ods for identifying substrates in vivo complicate analy-
tional-scanning peptide libraries revealed the overallsis. The majority of proteases are synthesized as
proteolytic activities in dust mite extracts, the specificzymogens and are activated only in specific subcellular
protease(s) responsible for these activities from com-compartments or upon stimulation. Furthermore, many
plex mixtures remained to be identified.proteases have endogenous inhibitors that attenuate
In order to retrieve the cysteine-protease(s) from thetheir destructive capacity. As proteolysis is regulated
dust mite extracts, Harris et al. turned to mechanism-posttranslationally, the evaluation of mRNA or polypep-
tide levels do not necessarily reflect their activity. To based probes that irreversibly label active enzymes [1].
